#United States #Cambridge #Harbour BioMed #antibody therapeutics #Dr. Ian Y. Liu

Harbour BioMed Appoints Dr. Ian Y. Liu as Global Head of Legal

Harbour BioMed, a global frontrunner in biopharmaceuticals focused on antibody therapies for immunology and oncology, has recently announced the appointment of Dr. Ian Y. Liu as the company’s Global Head of Legal. Based in the United States, Dr. Liu will play a pivotal role in the legal landscape of Harbour BioMed, reporting directly to the company’s founder and CEO, Dr. Jingsong Wang.

Dr. Liu's role as Senior Vice President will encompass a wide range of responsibilities aimed at safeguarding the company's interests. He will oversee business transactions, ensuring legal and regulatory compliance while facilitating seamless execution within Harbour BioMed’s operations. The strength of these legal strategies is vital as the company navigates an increasingly complex biopharmaceutical marketplace. In addition, Dr. Liu will lead the company’s global intellectual property strategy, playing an essential role in protecting the proprietary technologies and innovations developed by Harbour BioMed.

In his new position, Dr. Liu will manage all U.S.-related legal matters, which include not only prosecution and litigation of legal cases but also overseeing strategic growth initiatives in the highly competitive U.S. market. His extensive background equips him well for these tasks. Prior to joining Harbour BioMed, Dr. Liu honed his expertise in prestigious law firms such as Finnigan, Henderson, Farabow, Garrett Dunner, LLP, and KL Gates, LLP. His experience in patent applications, litigation, and due diligence has prepared him to face the evolving legal challenges in the biopharma sector.

Dr. Liu also has a solid corporate legal affairs background. He previously served as Head of Legal and Governmental Affairs at Simcere Pharmaceutical, where he successfully handled complex legal matters and engaged in high-level commercial negotiations that enhanced the organization’s success.

In welcoming Dr. Liu to the Harbour BioMed family, Dr. Jingsong Wang stated, "We are pleased to welcome Dr. Ian Y. Liu to Harbour BioMed. As we continue to expand our business globally, Dr. Liu’s expertise in intellectual property, business transactions, and regulatory affairs will be invaluable. His extensive legal knowledge and experience will be crucial in supporting our sustained growth in both U.S. and international markets, enhancing our position within a challenging industry landscape."

Expressing his enthusiasm for joining Harbour BioMed, Dr. Liu commented, "Harbour BioMed has always been at the forefront of drug discovery and development, business innovation, and globalization. It is a privilege and honor to become part of Harbour BioMed and I am looking forward to contributing to the company’s bright future."

Dr. Liu’s academic credentials include a Bachelor of Science degree from Fudan University, a Ph.D. from Worcester Polytechnic Institute, and a Juris Doctor from Suffolk University Law School. His diverse educational background adds to his unique capabilities in navigating the complexities of the biopharmaceutical field.

As Harbour BioMed continues to refine its portfolio, Dr. Liu’s strategic legal approach will be instrumental in supporting the company’s innovative efforts in antibody therapeutics. The proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in innovative formats, enabling product innovation in oncology treatment.

With Dr. Liu now at the helm of legal operations, Harbour BioMed is poised to enhance its long-term strategy, paving the way for new advancements in therapeutics that align with global health objectives. The integration of Dr. Liu’s expertise with the company's existing capabilities enhances its commitment to delivering groundbreaking therapies to patients worldwide.

For further insights into Harbour BioMed and its innovative approaches, please visit Harbour BioMed Website.